Announced by First Minister Nicola Sturgeon, the company will receive a Scottish Enterprise Regional Selective Assistance (RSA) grant to extend their Potassium Clavulanate (Clav) Plant, which produces penicillin.
The Irvine facility has been expanded to meet the growing demand from the developing world and emerging markets for antibiotics.
Speaking at the official opening of the new facility in Irvine, the First Minister said:
“GSK is a global leader in the development of medicines and a great example of a highly innovative company that is benefiting from what Scotland has to offer as an attractive location for global life sciences companies.
“Their further investment in Scotland is testament to our thriving life sciences industry and its position as a key growth sector for the Scottish economy. Their continued commitment across their sites in Scotland is proof of the skill and value of the Scottish workforce.”
Sir Andrew Witty, GSK CEO, said: “We’re delighted to be opening a new facility in Scotland, where we have a long-standing commitment to manufacturing, which will continue in the near and distant future. The impact of this new facility will be felt here and abroad, with more antibiotics produced for people in countries where this sort of medicine is desperately needed.”
Adrian Gillespie, Scottish Enterprise Managing Director of Operations said: “Today marks a significant milestone for GSK and Scotland’s life sciences sector. Since 2009 we’ve worked intensively with the company helping deliver its ambitious growth plans. “This latest support of £1.5 million RSA funding helped secure the company’s investment in Scotland and the creation of 55 new jobs. GSK is an important contributor to the Scottish economy and together we will continue to support its growth ambition in Scotland.”
- 47 Little France Crescent
- EH16 4TJ
Enquiries: Edinburgh BioQuarter Reception
T: +44 (0)131 658 5150
- Apex House
- 99 Haymarket Terrace
- Edinburgh, EH12 5HD
Enquiries: Edinburgh Office
T: 0845 607 8787